Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/61469
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3397]
Metadata
Show full item record
PS1/γ-SECRETASE-MEDIATED CADHERIN CLEAVAGE INDUCES β-CATENIN NUCLEAR TRANSLOCATION AND OSTEOGENIC DIFFERENTIATION OF HUMAN BONE MARROW STROMAL CELLS
Author
Affilliation
Federal University of Rio de Janeiro. Institute of Biomedical Sciences. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biomedical Sciences. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. Rio de Janeiro, RJ, Brazil / National Institute of Cancer. Institute of Medical Biochemistry. Rio de Janeiro, RJ, Brazil.
National Institute of Cancer. Molecular Carcinogenesis Program. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Evandro Chagas Clinical Research Institute. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biomedical Sciences. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biomedical Sciences. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biomedical Sciences. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. Rio de Janeiro, RJ, Brazil.
National Institute of Cancer. Molecular Carcinogenesis Program. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biomedical Sciences. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biomedical Sciences. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biomedical Sciences. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. Rio de Janeiro, RJ, Brazil / National Institute of Cancer. Institute of Medical Biochemistry. Rio de Janeiro, RJ, Brazil.
National Institute of Cancer. Molecular Carcinogenesis Program. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Evandro Chagas Clinical Research Institute. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biomedical Sciences. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biomedical Sciences. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biomedical Sciences. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. Rio de Janeiro, RJ, Brazil.
National Institute of Cancer. Molecular Carcinogenesis Program. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biomedical Sciences. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biomedical Sciences. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. Rio de Janeiro, RJ, Brazil.
Abstract
Bone marrow stromal cells (BMSCs) are considered a promising tool for bone bioengineering. However, the mechanisms controlling osteoblastic commitment are still unclear. Osteogenic differentiation of BMSCs requires the activation of 𝛽-catenin signaling, classically known to be regulated by the canonical Wnt pathway. However, BMSCs treatment with canonical Wnts in vitro does not always result in osteogenic differentiation and evidence indicates that a more complex signaling pathway, involving cadherins, would be required to induce 𝛽-catenin signaling in these cells. Here we showed that Wnt3a alone did not induce TCF activation in BMSCs, maintaining the cells at a proliferative state. On the other hand, we verified that, upon BMSCs osteoinduction with dexamethasone, cadherins were cleaved by the PS1/𝛾-secretase complex at the plasma membrane, and this event was associated with an enhanced 𝛽-catenin translocation to the nucleus and signaling. When PS1/𝛾-secretase activity was inhibited, the osteogenic process was impaired. Altogether, we provide evidence that PS1/𝛾-secretase-mediated cadherin cleavage has as an important role in controlling 𝛽-catenin signaling during the onset of BMSCs osteogenic differentiation, as part of a complex signaling pathway responsible for cell fate decision. A comprehensive map of these pathways might contribute to the development of strategies to improve bone repair.
Share